Literature DB >> 8564998

Tolerance to opioid analgesics: clinical aspects.

R K Portenoy1.   

Abstract

Tolerance is a complex phenomenon with important therapeutic implications. Understanding of its clinical aspects has been hampered by inadequate communication between clinicians, who have acquired striking observations relevant to the stability of the dose-response relationship in patients with pain, and investigators who have extensively studied animal models or drug effects in former addicts. In the clinical setting, it is now clear that the loss of analgesic effects over time has a differential diagnosis, only one component of which is tolerance. Evidence from a variety of sources suggests that true pharmacological tolerance to the analgesic effects of opioids is an uncommon cause for the need to escalate the opioid dose to maintain analgesic effects. Tolerance to non-analgesic effects appears to occur more reliably, but this phenomenon, too, is neither uniform nor simple. Some patients who appear to have developed tolerance to these adverse effects demonstrate a remarkable lack of tolerance when the pain is eliminated by some unrelated mechanism. The disparity between these clinical observations and the experimental literature on tolerance suggests that mechanisms related to the pain itself may have an important modulating effect on these phenomena. From the clinical perspective, the disparity emphasizes the need to avoid generalization from the laboratory to the clinic without adequate confirmation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8564998

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  11 in total

1.  Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Annemarie Ledeboer; Julie Wieseler-Frank; Erin D Milligan; Steven F Maier
Journal:  Brain Behav Immun       Date:  2006-12-18       Impact factor: 7.217

2.  [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].

Authors:  Vicente Valentín Maganto; Carlos Camps Herrero; Joan Carulla Torrent; Javier Cassinello Espinosa; Javier Dorta Delgado; Carlos Jara Sánchez; José Andrés Moreno Nogueira
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

3.  [Oral controlled-release oxycodone for the treatment of chronic pain. Data from 4196 patients].

Authors:  J Gaertner; M Frank; B Bosse; R Sabatowski; F Elsner; T Giesecke; L Radbruch
Journal:  Schmerz       Date:  2006-02       Impact factor: 1.107

Review 4.  Opioids for neuropathic pain.

Authors:  Nathaniel Katz; Christine Benoit
Journal:  Curr Pain Headache Rep       Date:  2005-06

5.  Midazolam exacerbates morphine tolerance and morphine-induced hyperactive behaviors in young rats with burn injury.

Authors:  Li Song; Shuxing Wang; Yunxia Zuo; Lucy Chen; Jeevendra A Martyn; Jianren Mao
Journal:  Brain Res       Date:  2014-04-05       Impact factor: 3.252

6.  Differential tolerance to morphine antinociception in assays of pain-stimulated vs. pain-depressed behavior in rats.

Authors:  Ahmad A Altarifi; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2014-12-18       Impact factor: 4.432

Review 7.  Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Authors:  Michael M Morgan; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

8.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

9.  Opioids switching with transdermal systems in chronic cancer pain.

Authors:  C Aurilio; M C Pace; V Pota; P Sansone; M Barbarisi; E Grella; M B Passavanti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-07

10.  Ensuring competency in end-of-life care: controlling symptoms.

Authors:  Frank D Ferris; Charles F Von Gunten; Linda L Emanuel
Journal:  BMC Palliat Care       Date:  2002-07-30       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.